SLN vs. ORIC, SIGA, ZYME, LBPH, AVTE, BCYC, LYEL, NUVB, ATXS, and YMAB
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include ORIC Pharmaceuticals (ORIC), SIGA Technologies (SIGA), Zymeworks (ZYME), Longboard Pharmaceuticals (LBPH), Aerovate Therapeutics (AVTE), Bicycle Therapeutics (BCYC), Lyell Immunopharma (LYEL), Nuvation Bio (NUVB), Astria Therapeutics (ATXS), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
ORIC Pharmaceuticals (NASDAQ:ORIC) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.
ORIC Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
ORIC Pharmaceuticals currently has a consensus target price of $19.80, suggesting a potential upside of 158.15%. Silence Therapeutics has a consensus target price of $57.25, suggesting a potential upside of 164.80%. Given ORIC Pharmaceuticals' higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than ORIC Pharmaceuticals.
95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 5.3% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Silence Therapeutics had 2 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 3 mentions for Silence Therapeutics and 1 mentions for ORIC Pharmaceuticals. Silence Therapeutics' average media sentiment score of 0.59 beat ORIC Pharmaceuticals' score of -0.05 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media.
ORIC Pharmaceuticals has a net margin of 0.00% compared to ORIC Pharmaceuticals' net margin of -171.41%. Silence Therapeutics' return on equity of -42.71% beat ORIC Pharmaceuticals' return on equity.
Silence Therapeutics has higher revenue and earnings than ORIC Pharmaceuticals. Silence Therapeutics is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ORIC Pharmaceuticals received 24 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Silence Therapeutics an outperform vote while only 65.22% of users gave ORIC Pharmaceuticals an outperform vote.
Summary
ORIC Pharmaceuticals and Silence Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Silence Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
